The Drug-Induced Respiratory Disease Website and App

Frequency - Incidence

Incidence of respiratory adverse event(s) due to the specific drug as assessed by number of reported/published cases in the literature. Red digits in stars indicate: 0 = Very rare, questionable signal · 1 = < 10 cases · 2 = 10-50 cases · 3 = 50–100 cases · 4 = 100-200 cases · 5 = >200 cases

Evidence level/grade

Evidence level for respiratory adverse event(s) due to the specific drug as estimated using Hill’s (1965), Naranjo’s (1981), and Bégaud’s (1985) criteria applied to published cases. Blue digits in stars indicate: 0 = Questionable · 1 = Low · 2 = Moderate · 3 = Robust · 4 = Definite · 5 = Unquestionable, pathognomonic

I.a

Pneumonitis (interstitial lung disease/ILD)

Publications

Masago T, Watanabe T, Nemoto R, Motoda K

Interstitial pneumonitis induced by bicalutamide given for prostate cancer.

International journal of clinical oncology 2011 Dec;16;763-5 — 2011 Dec — 763-5

Shioi K, Yoshida M, Sakai N

Interstitial pneumonitis induced by bicalutamide and leuprorelin acetate for prostate cancer.

International journal of urology : official journal of the Japanese Urological Association 2003 Nov;10;625-6 — 2003 Nov — 625-6

Bennett CL, Raisch DW, Sartor O

Pneumonitis associated with nonsteroidal antiandrogens: presumptive evidence of a class effect.

Annals of internal medicine 2002 Oct 01;137;625 — 2002 Oct 01 — 625

McCaffrey JA, Scher HI

Interstitial pneumonitis following bicalutamide treatment for prostate cancer.

The Journal of urology 1998 Jul;160;131 — 1998 Jul — 131